QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Roivant Sciences Stock Price, News & Analysis (NASDAQ:ROIV)

$9.09
-0.01 (-0.11%)
(As of 11/28/2023 ET)
Compare
Today's Range
$8.88
$9.15
50-Day Range
$8.38
$13.19
52-Week Range
$5.01
$13.24
Volume
7.08 million shs
Average Volume
4.50 million shs
Market Capitalization
$7.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33

Roivant Sciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
68.7% Upside
$15.33 Price Target
Short Interest
Healthy
5.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.16mentions of Roivant Sciences in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$221.24 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.55) to ($1.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

193rd out of 949 stocks

Pharmaceutical Preparations Industry

78th out of 435 stocks


ROIV stock logo

About Roivant Sciences Stock (NASDAQ:ROIV)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

ROIV Stock Price History

ROIV Stock News Headlines

Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Q2 2024 Roivant Sciences Ltd Earnings Call
Roivant Sciences earnings preview: what Wall Street is expecting
Roivant Sciences Ltd Ordinary Shares
See More Headlines
Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
11/28/2023
Next Earnings (Estimated)
2/12/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ROIV
Fax
N/A
Employees
904
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.33
High Stock Price Target
$23.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+68.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-1,009,030,000.00
Net Margins
-951.77%
Pretax Margin
-1,177.62%

Debt

Sales & Book Value

Annual Sales
$61.28 million
Book Value
$2.11 per share

Miscellaneous

Free Float
766,941,000
Market Cap
$7.31 billion
Optionable
Not Optionable
Beta
1.32
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Matthew Gline (Age 39)
    CEO & Director
    Comp: $1.77M
  • Dr. Eric Venker M.D. (Age 36)
    Pharm.D., President & COO
    Comp: $1.28M
  • Dr. Mayukh Sukhatme M.D. (Age 47)
    President & Chief Investment Officer
    Comp: $1.72M
  • Mr. Richard Pulik (Age 44)
    Chief Financial Officer
  • Ms. Rakhi KumarMs. Rakhi Kumar (Age 43)
    Chief Accounting Officer
  • Dr. Huafeng Xu Ph.D.
    Chief Technology Officer
  • Mr. Josh Chen
    General Counsel
  • Ms. Kelly Graff
    Head of People
  • Ms. Marianne L. Romeo (Age 55)
    Head of Global Transactions & Risk Management
  • Mr. Alex Gasner
    Executive Vice President of Roivant Health














ROIV Stock Analysis - Frequently Asked Questions

Should I buy or sell Roivant Sciences stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ROIV shares.
View ROIV analyst ratings
or view top-rated stocks.

What is Roivant Sciences' stock price target for 2024?

9 Wall Street research analysts have issued 1-year price objectives for Roivant Sciences' shares. Their ROIV share price targets range from $10.00 to $23.00. On average, they anticipate the company's stock price to reach $15.33 in the next year. This suggests a possible upside of 68.7% from the stock's current price.
View analysts price targets for ROIV
or view top-rated stocks among Wall Street analysts.

How have ROIV shares performed in 2023?

Roivant Sciences' stock was trading at $7.99 on January 1st, 2023. Since then, ROIV shares have increased by 13.8% and is now trading at $9.09.
View the best growth stocks for 2023 here
.

When is Roivant Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our ROIV earnings forecast
.

How were Roivant Sciences' earnings last quarter?

Roivant Sciences Ltd. (NASDAQ:ROIV) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.10. The firm earned $21.60 million during the quarter, compared to the consensus estimate of $24.49 million. Roivant Sciences had a negative net margin of 951.77% and a negative trailing twelve-month return on equity of 73.04%. The company's quarterly revenue was up 402.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.48) earnings per share.

Who are Roivant Sciences' major shareholders?

Roivant Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include SB Investment Advisers UK Ltd. (9.46%), FMR LLC (5.04%), Morgan Stanley (2.50%), Rubric Capital Management LP (1.36%), Adage Capital Partners GP L.L.C. (0.80%) and Loomis Sayles & Co. L P (0.26%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Global Investors Lp Viking, Keith S Manchester, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy.
View institutional ownership trends
.

How do I buy shares of Roivant Sciences?

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ROIV) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -